Prof. Wu Xiaohua (吴小华) — Cervical Cancer, Ovarian Cancer & Gynecologic Oncology | Fudan University Cancer Hospital Shanghai
In the field of gynecologic oncology, few achievements carry the international weight of having a clinical standard cited in the guidelines of the National Comprehensive Cancer Network (NCCN) — the most widely referenced cancer treatment guidelines in the world. Prof. Wu Xiaohua (吴小华) at Fudan University Cancer Hospital Shanghai has achieved precisely this: the “Fudan Standard” for fertility-sparing surgery in cervical cancer, developed by his team, has been cited in NCCN guidelines — a recognition that places his work at the forefront of international gynecologic oncology practice.
As the Chief Multidisciplinary Treatment (MDT) Expert for Gynecologic Oncology at Fudan University Cancer Hospital — one of China's premier cancer centers — Prof. Wu leads a program that is remarkable not only for its clinical innovation but for its sheer volume: his team has completed over 500 cases of abdominal radical trachelectomy (fertility-sparing cervical cancer surgery), making it the highest-volume single center for this procedure in the world. His team also performs over 45% of all ovarian cancer surgeries in Shanghai — a concentration of expertise that reflects the program's national and international reputation.
Specialty Focus
- Cervical cancer: radical surgery, fertility-sparing radical trachelectomy, minimally invasive approaches
- Ovarian cancer: cytoreductive surgery, HIPEC, PARP inhibitor management
- Endometrial cancer: surgical staging, sentinel lymph node mapping, fertility-sparing options
- Vulvar and vaginal cancers
- Gynecologic cancer multidisciplinary treatment (MDT) coordination
- Recurrent gynecologic cancers: pelvic exenteration and salvage surgery
Academic & Clinical Titles
- Chief Physician & Professor, Department of Gynecologic Oncology, Fudan University Cancer Hospital (Shanghai Cancer Center)
- Chief MDT Expert, Gynecologic Oncology, Fudan University Cancer Hospital
- Developer of the “Fudan Standard” for fertility-sparing cervical cancer surgery, cited in NCCN guidelines
- Leader of the world's highest-volume single center for abdominal radical trachelectomy (>500 cases)
- Team performs >45% of all ovarian cancer surgeries in Shanghai
The Fudan Standard: NCCN-Cited Fertility-Sparing Surgery
Cervical cancer disproportionately affects younger women — many of whom have not yet completed their families at the time of diagnosis. For decades, the standard surgical treatment for early-stage cervical cancer was radical hysterectomy, which permanently eliminates the possibility of future pregnancy. The development of fertility-sparing alternatives — specifically radical trachelectomy, which removes the cervix while preserving the uterus — has transformed the options available to young women with early cervical cancer who wish to preserve their fertility.
Prof. Wu Xiaohua's team at Fudan University Cancer Hospital has become the global leader in this procedure. With over 500 completed cases of abdominal radical trachelectomy — the most technically demanding approach, which provides the widest surgical margins and is preferred for larger tumors — his center has accumulated more experience with this operation than any other single institution in the world.
The “Fudan Standard” represents the clinical criteria and technical approach developed by Prof. Wu's team based on this unparalleled experience: defining which patients are appropriate candidates for fertility-sparing surgery, what surgical technique achieves the best balance of oncological safety and fertility preservation, and what follow-up protocols are required. The citation of this standard in NCCN guidelines — the global benchmark for cancer treatment recommendations — is a formal international recognition that Prof. Wu's work has contributed to the global evidence base for cervical cancer management.
For young women with early-stage cervical cancer who wish to preserve their fertility, Prof. Wu's program offers the most experienced and internationally validated fertility-sparing surgical option available anywhere in the world.
Cervical Cancer: Comprehensive Treatment Beyond Fertility Preservation
Prof. Wu's expertise extends across the full spectrum of cervical cancer management, not only fertility-sparing cases:
Early-stage cervical cancer (Stages IA–IB2): Radical hysterectomy with pelvic lymphadenectomy remains the standard surgical treatment for patients who do not require fertility preservation. Minimally invasive approaches (laparoscopic or robotic) are available for selected cases. Sentinel lymph node mapping is increasingly used to reduce the morbidity of full lymphadenectomy.
Locally advanced cervical cancer (Stages IB3–IVA): Concurrent chemoradiation (cisplatin-based) with brachytherapy is the standard of care. Immunotherapy (pembrolizumab) has demonstrated benefit in combination with chemoradiation for high-risk locally advanced disease (KEYNOTE-A18 trial) and is now incorporated into guidelines.
Metastatic and recurrent cervical cancer: Pembrolizumab + chemotherapy ± bevacizumab for PD-L1-positive tumors (KEYNOTE-826 trial) has transformed first-line treatment of metastatic cervical cancer. Tisotumab vedotin (an antibody-drug conjugate targeting tissue factor) is approved for recurrent/metastatic disease after prior therapy. Pelvic exenteration — an extensive surgical procedure for selected patients with central pelvic recurrence — is performed at Prof. Wu's center for carefully selected candidates.
Molecular profiling: PD-L1 testing (CPS score) is essential for all metastatic/recurrent cervical cancer patients to guide immunotherapy eligibility. MSI-H/dMMR testing and comprehensive NGS profiling are recommended.
Ovarian Cancer: Shanghai's Highest-Volume Program
Prof. Wu's team performs over 45% of all ovarian cancer surgeries in Shanghai — a concentration of volume that reflects both the program's reputation and the clinical reality that high surgical volume correlates with better outcomes in ovarian cancer cytoreduction. The goal of complete cytoreduction (R0 resection, no visible residual disease) is the single most important prognostic factor in advanced ovarian cancer, and achieving it consistently requires both surgical skill and the institutional infrastructure to support complex, extended operations.
Prof. Wu's ovarian cancer program encompasses:
- Primary debulking surgery (PDS) for newly diagnosed advanced ovarian cancer
- Interval debulking surgery (IDS) following neoadjuvant chemotherapy
- HIPEC (hyperthermic intraperitoneal chemotherapy) for selected patients
- BRCA/HRD testing and PARP inhibitor maintenance therapy coordination
- Secondary cytoreductive surgery for selected recurrent cases
- Clinical trial access for novel ovarian cancer therapies
For international patients with ovarian cancer, Prof. Wu's program offers the combination of high surgical volume, comprehensive molecular testing, and access to the full range of maintenance therapies — including PARP inhibitors — that defines a world-class ovarian cancer center.
Multidisciplinary Treatment: The MDT Approach
As Chief MDT Expert for Gynecologic Oncology at Fudan University Cancer Hospital, Prof. Wu leads a multidisciplinary team that brings together gynecologic oncology surgery, medical oncology, radiation oncology, pathology, radiology, and genetic counseling for every complex case. The MDT approach ensures that treatment decisions reflect the full range of available options and the collective expertise of multiple specialists — rather than the perspective of a single physician.
For international patients, CMCS coordinates submission of cases to Prof. Wu's MDT before any travel to Shanghai is required, enabling a comprehensive treatment recommendation to be developed based on the patient's records.
Who Should Consider Consulting Prof. Wu Xiaohua
- Young women with early-stage cervical cancer who wish to preserve fertility and are considering radical trachelectomy
- Patients with cervical cancer at any stage seeking expert surgical evaluation or second opinion
- Patients with locally advanced cervical cancer being evaluated for chemoradiation + immunotherapy
- Patients with recurrent or metastatic cervical cancer seeking access to pembrolizumab-based regimens or tisotumab vedotin
- Patients with advanced ovarian cancer seeking high-volume cytoreductive surgery
- Patients with ovarian cancer being evaluated for HIPEC or secondary cytoreduction
- Patients with endometrial cancer seeking surgical staging or fertility-sparing options
How CMCS Connects You with Prof. Wu Xiaohua
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Wu Xiaohua for international patients with cervical cancer, ovarian cancer, and other gynecologic malignancies. Our team manages the full coordination process — from remote case review and medical record translation to MDT submission, appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including pathology reports, MRI pelvis, CT chest/abdomen/pelvis, PD-L1 and molecular profiling results, tumor markers (CA-125, SCC, CEA as appropriate), and prior treatment summaries. Prof. Wu's team can conduct an initial remote assessment before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation case review and MDT submission
- Appointment coordination with Prof. Wu Xiaohua at Fudan University Cancer Hospital
- On-site interpretation during consultations and procedures
- BRCA/HRD testing and PARP inhibitor access coordination
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Wu Xiaohua
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comments